Prevention and treatment of influenza and ARVI in pregnant women

Influenza and acute respiratory viral infections continue to occupy leading positions in the structure of infectious pathology. The high risk categories of the disease include pregnant women who, due to hormonal and physiological changes occurring in the body during the period of carrying a child, are at risk of developing severe/complicated course of respiratory infections, especially in the third trimester of pregnancy. A small number of medications that are effective and allowed to be used in women during gestation make it relevant to develop and implement new schemes for the prevention and treatment of acute respiratory viral infections in pregnant women. To date, one of the promising directions is the use of drugs that have antiviral properties and activate the functioning of the immune system, which would prevent the development of complications and prevent reproductive losses. The results of scientific studies devoted to evaluating the effectiveness and safety of the use of recombinant interferon α-2b with antioxidants for the prevention and treatment of influenza and acute respiratory infections in pregnant women are presented. The preventive use of recombinant interferon α-2b with antioxidants preparations (rectal suppositories or gel for external and topical use) in the form of mono- or combined systemic and topical forms makes it possible to achieve a significant reduction in the incidence of influenza and other acute respiratory infections, including COVID-19, reduce the frequency of pregnancy complications, increase the number of favorable perinatal outcomes and the birth of healthy children. The use of recombinant interferon α-2b drugs as a therapeutic agent in pregnant women in case of respiratory infections can reduce the overall duration of the disease and the period of intoxication, reduce the frequency of severe forms and complications of respiratory infections, significantly reduce the risk of premature birth and the birth of children with low body weight, reduce the frequency of exacerbations of chronic, including extragenital diseases of pregnant women. The conclusion is made about the expediency of including recombinant interferon α-2b with antioxidants drugs in the complex of preventive measures and basic therapy of influenza and acute respiratory infections in pregnant women.

1. Timchenko V. N., Sukhovetskaya V. F., Chernova T. M., Barakina E. V., Pochinyaeva L. M., Malinovskaya V. V., Semenenko T. A., Shuvalov A. N. The role of early etiological decoding of acute respiratory viral infections in the choice of antiviral therapy in children in hospital // Pediatriya. Zhurnal im. G. N. Speranskogo. (Pediatrics. The journal named after G. N. Speransky). 2020; 99 (1): 100-106. (In Russ.) DOI:10.24110/0031-403X-2020-99-1-100-106.

2. Guidelines «Influenza and other acute respiratory infections during the ongoing COVID-19 pandemic: prevention and treatment». Moscow, 2022. (In Russ.)

3. Semenenko T. A., Akimkin V. G., Burtseva E. I., Nozdracheva A. V., Simonova E. G., Tutelyan A. V., et al. Characteristics of the Epidemic Situation Associated with Acute Respiratory Viral Infections in the Russian Federation during the Pandemic Spread of COVID-19 // Epidemiologiya i Vakcinoprofilaktika (Epidemiology and Vaccinal Prevention). 2022; 21 (4): 4-15 (In Russ.) https://doi:10.31631/2073-3046-2022-21-4-4-15.

4. Guidelines «Influenza and SARS: modern etiotropic and pathogenetic therapy. Algorithms for providing medical care to patients». Moscow, 2019. (In Russ.)

5. Sokolov D. I., Stepanova O. I., Selkov S. I. The role of the different subpopulations of CD4+ Т-lymphocytes during pregnancy // Medical Immunology (Russia). 2016; 18 (6): 521-536. (In Russ.) https://doi.org/10.15789/1563-0625-2016-6-521-536.

6. Костинов М. П., Хромова Е. А., Сависько А. А., Костинова А. М. Функциональные особенности иммунной системы при физиологическом течении беременности и их взаимосвязь с вакцинацией против гриппа // Consilium Medicum. 2016; 18 (6): 59-62.

7. Abdullahi H., Elnahas A., Konje J. C. Seasonal influenza during pregnancy // Eur J Obstet Gynecol Reprod Biol. 2021; 258: 235-239. DOI:10.1016/j.ejogrb.2021.01.005.

8. Fuhler G. M. The immune system and microbiome in pregnancy // Best Pract Res Clin Gastroenterol. 2020; 44-45: 101671. DOI:10.1016/j.bpg.2020.101671.

9. Zapolskikh A. M., Lytkina I. N., Mikheeva I. V., Malyshev N. A., Bazarova M. V., Serobyan A. G. Clinical and epidemiological characteristics of influenza A(H1N1) in pregnant women // Epidemiology and vaccinoprophylaxis. 2014; 1 (74): 66-73. (In Russ.)

10. Avdeeva M. G., Gafurova O. R. Highly pathogenic influenza A(H1N1) in pregnant women, the effect on the outcomes of childbirth. 2018; 23 (3): 119-125. (In Russ.) https://doi.org/10.18821/1560-9529-2018-23-3-119-125.

11. Nozdracheva A. V., Gotvyanskaya T. P., Semenenko A. V., Afonin S. A. The main directions of nonspecific prevention of infectious diseases // Sanitarnyj vrach (The sanitary doctor). 2021; 11: 24-37. (In Russ.) DOI:10.33920/med-08-2111-02.

12. Sel'kova E. P., Iakovlev V. N., Semenenko T. A., Filatov N. N., Gotvianskaia T. P., Danilina G. A., Pantiukhova T. N., Nikitina G. I., Tur'ianov M. K. Еvaluation of amyxin effect in prophylaxis of acute respiratory viral infections // Zhurnal mikrobiologii, jepidemiologii i immunobiologii (Journal of Microbiology Epidemiology Immunobiology). 2001; 3: 42-46. (In Russ.) EDN: MPGUPV.

13. Romantsov M. G., Selkova E. P., Garashchenko M. V., Semenenko T. A., Shuldyakov A. A., Kondratieva E. I., etc. Increasing the natural resistance of children in order to prevent influenza and ARVI (results of multicenter randomized trials) // Antibiotiki i himioterapiya (Antibiotics and chemotherapy). 2009; 54 (9-10): 37-41. (In Russ.)

14. Immunotherapy. Guidelines for doctors / R. M. Khaitov, R. I., Ataullakhanov, A. E. Shulzhenko, ed. Moscow: GEOTAR-Media, 2020. 702 p. (In Russ.)

15. Kuklina L. V., Kravchenko E. N., Kolereva M. A., Zadorozhnaya E. A., Vyzhlova E. N., Baranov I. I. Risk factors for the incidence of acute respiratory viral infections in pregnant women. The effectiveness of preventive measures // Voprosy ginekologii, akusherstva i perinatologii (Issues of gynecology, obstetrics and perinatology). 2021; 20 (3): 85-91. (In Russ.) DOI:10.20953/1726-1678-2021-3-85-91.

16. Nesterova I. V., Kovaleva S. V., Chudilova G. A., etc. Efficacy and safety of Viferon in mono- and combined immunotherapy of immunocompromised children with recurrent respiratory infections // Pharmateca. 2017; 4 (337): 54-62. (In Russ.)

17. Malinovskaya V. V., Baranov I. I., Vyzhlova E. N., Shuvalov A. N. Treatment of acute respiratory infections in pregnant women // Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2019; 4 (7): 72-78. (In Russ.) DOI:10.24411/2303-96982019-14006.

18. Ruzhentsova T. A., Khavkina D. A., Chukhlyaev P. V., Shushakova E. K. Efficacy and safety of the drug based on interferon alpha-2b with vitamins C and E for the treatment and prevention of congenital pneumonia // Мedicinskij alfavit (Medical Alphabet). 2020; 18: 61-66. (In Russ.) DOI:10.33667/2078-5631-2020-18-61-66.

19. Belokrinitskaya T. E., Liga V. F., Trubitsyna A. Yu., Tarbaeva D. A. Drug prevention of influenza in pregnant women // Voprosy ginekologii, akusherstva i perinatologii (Issues of gynecology, obstetrics and perinatology). 2012; 11(4): 31-36. (In Russ.)

20. Bocharova I. I., Zarochentseva N. V., Aksenov A. N., Malinovskaya V. V., Vyzhlova E. N., Semenenko T. A., etc. Prevention of acute respiratory viral infections in newborns and their mothers in the context of a pandemic of a new coronavirus infection // Voprosy ginekologii, akusherstva i perinatologii (Gynecology, Obstetrics and Perinatology). 2021; 20 (2): 66-74. (In Russ.) DOI:10.20953/1726-1678-2021-2-66-74.

21. Gabdullina R. Z. Treatment and prevention of influenza A/H1N1 in pregnant women // Vestnik Ferona (Bulletin of Feron). 2012; 2: 26-34. (In Russ.)

22. Kostinov M. P., Meshcheryakova A. K., Kytko O. V. Malinovskaya V. V., etc. Clinical effect of the use of VIFERON® drugs in pregnant women with acute respiratory infection // Glavnyj vrach Yuga Rossii (Chief Physician of the South of Russia). 2014; 1 (38): 43. (In Russ.)

23. Martynova G. P., Ikkes L. A., Bogvilene Ya. A. Clinical efficacy of the combined use of two dosage forms of recombinant interferon a-2b in the treatment of infectious mononucleosis in children // Detskie infekci (Childhood infections). 2019; 18 (1): 42-47. (In Russ.) https://doi.org/10.22627/2072-8107-2019-18-1-42-47.

24. Kravchenko E. N., Kuklina L. V., Ovchinnikova E. M., Chebakova V. Yu., et al. COVID-19 in pregnancy: special characteristics of the course and rational therapy with recombinant interferon alfa-2b formulations // Rossiiskii vestnik akushera-ginekologa (Russian Bulletin of Obstetrician-Gynecologist). 2021; 21 (5): 96-101. (In Russ.) https://doi.org/10.17116/rosakush20212105196.

25. Kostinov M. P., Lukachev I. V., Meshcheryakova A. K., Dmitrieva E. V. etc. Induction of innate and adaptive immunity effectors during treatment with a tropical form of recombinant interferon-A2 in respiratory infections in pregnant women // Zhurnal mikrobiologii, epidemiologii i immunobiologii. (Journal of Microbiology, Epidemiology and Immunobiology). 2017; 94 (2): 38-45. (In Russ.)

26. Kostinov M. P., Lukachev I. V., Meshcheryakova A. K. etc. Prevention of complications in pregnant women with mild and moderate severity of acute respiratory infections // Epidemiologiya i vakcinoprofilaktika (Epidemiology and vaccinoprophylaxis). 2018; 1 (98): 62-73. (In Russ.)